IDEXX Laboratories, Inc. (IDXX)
Meet the Little-Known S&P 500 Stock That Has Rocketed 10,230% Higher Since 2000
Healthcare diagnostics equipment manufacturer, Idexx Laboratories (IDXX -1.54%), is the global leader in pet care.
Should You Retain IDEXX Stock in Your Portfolio for Now?
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'
Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significant growth and new revenue streams. IDEXX's share repurchase program is robust, with $837 million repurchased in FY24 and a plan for $1.5 billion in FY25.
IDEXX Laboratories: A Top Dog In The Pet Care Market
The pet care industry is growing, with increasing pet ownership and spending, especially in emerging markets, providing IDEXX with significant growth opportunities. IDEXX Laboratories is the market leader with a highly profitable business model, operating leverage, and recurring revenues. Once a customer starts using an IDEXX instrument, it is tied to the IDEXX ecosystem.
Should You Hold IDEXX Stock in Your Portfolio for Now?
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
IDEXX Laboratories And Its Real Value
IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years.
Why Idexx Labs Stock Rocketed Higher This Week
Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future
IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage.
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices
Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices.
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx: Q4 EPS, Revenue Beat Forecast
Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million.
